image credit: Pixabay

Developing a COVID-19 antigen test

May 15, 2020

Avacta is developing cancer immunotherapeutics, and diagnostics, based on its Affimer technology. The Affimer® platform is an alternative to antibodies derived from a small human protein, designed to address many of the shortcomings and negative performance issues associated with antibodies, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size; and cost.

Read More on The Medical News